Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 7710 results

  1. Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (MTG40)

    Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers.

    Medical technologies guidance
    Published
    10 January 2019
    View recommendations

    Sections for MTG40

  2. Curos for preventing infections when using needleless connectors (MTG44)

    Evidence-based recommendations on Curos for preventing infections when using needleless connectors.

    Medical technologies guidance
    Published
    9 May 2019
    View recommendations

    Sections for MTG44

  3. ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)

    Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.

    Medical technologies guidance
    Last updated
    21 July 2021
    View recommendations

    Sections for MTG33

  4. Aflibercept for untreated retinopathy in babies born preterm TS ID 11943

      Status ...

    Technology appraisal guidance
    Topic selection

  5. The geko device for reducing the risk of venous thromboembolism (MTG19)

    Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.

    Medical technologies guidance
    Published
    25 June 2014
    View recommendations

    Sections for MTG19

  6. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.

    Medical technologies guidance
    Last updated
    1 March 2015
    View recommendations

    Sections for MTG22

  7. Eszopiclone for treating insomnia TS ID 12020

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040

    Awaiting development [GID-TA11591] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors TSID 12064

    Awaiting development [GID-TA11594] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036

    Awaiting development [GID-TA11596] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

    In development [GID-TA10620] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development [GID-TA10971] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development [GID-TA11438] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development [GID-TA11402] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: TBC

    Technology appraisal guidance
    In development